Lv5
900 积分 2024-09-30 加入
Anti–CTLA-4 therapy broadens the melanoma-reactive CD8 + T cell response
1天前
已完结
[Chinese expert consensus on clinical practice of MET detection in non-small cell lung cancer]
9天前
已完结
[Chinese expert consensus on MET immunohistochemistry detection and interpretation standards for non-small cell lung cancer(2023 version)]
9天前
已完结
SO-12 Nivolumab (NIVO) plus ipilimumab (IPI) combination therapy in patients with advanced hepatocellular carcinoma (aHCC): 5-year results from CheckMate 040
11天前
已完结
Nivolumab plus ipilimumab combination therapy in patients with advanced hepatocellular carcinoma previously treated with sorafenib: 5-year results from CheckMate 040
11天前
已完结
Arterial chemotherapy for hepatocellular carcinoma in China: consensus recommendations
11天前
已完结
Adjuvant sintilimab in resected high-risk hepatocellular carcinoma: a randomized, controlled, phase 2 trial
11天前
已完结
肝细胞癌国内外临床实践指南的比较与解读
11天前
已完结
Immunotherapies for hepatocellular carcinoma
11天前
已完结
The immunological and metabolic landscape in primary and metastatic liver cancer
11天前
已完结
皖公网安备34019202002308
